

## Literaturverzeichnis

1. Dobson, C., A. Sali, and M. Karplus, *Protein folding: a perspective from theory and experiment*. Amgew. Chem. Int. Eng., 1998. **37**: p. 868-893.
2. Wolynes, P., J. Onuchic, and D. Thirumalai, *Navigating the folding routes*. Science, 1995. **267**: p. 1619-1620.
3. Dill, K. and H. Chan, *From Levinthal to pathways to funnels*. Nature Struct. Biol., 1997. **4**: p. 10-19.
4. Radford, S. and C. Dobson, *From computer simulations to human disease: emerging themes in protein folding*. Cell, 1999. **97**: p. 291-298.
5. Baldwin, R., *Protein folding: matching speed and stability*. Nature, 1994. **369**: p. 183-184.
6. Bukau, B. and A. Horwich, *The Hsp 70 and Hsp 60 chaperone machines*. Cell, 1998. **92**: p. 351-366.
7. Hartl, F. and M. Hayer-Hartl, *Molecular chaperones in the cytosol: from nascent chain to folded protein*. Science, 2002. **295**: p. 1852-1858.
8. Ellis, R., *Macromolecular crowding: an important but neglected aspect of the intracellular environment*. Curr. Opin. Struct. Biol., 2001. **11**: p. 114-119.
9. Goldberg, A., *Protein degradation and protection against misfolded or damaged proteins*. Nature, 2003. **426**(18): p. 895-899.
10. Prouty, W. and A. Goldberg, *Fate of abnormal proteins in E. coli: accumulation in intracellular granules before catabolism*. Nature New Biol., 1972. **240**: p. 147-150.
11. Sherman, M. and A. Goldberg, *Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases*. Neuron, 2001. **29**: p. 15-32.
12. Ciechanover, A., *The ubiquitin-proteasome pathway: on protein death and cell life*. EMBO, 1998. **17**(24): p. 7151-60.
13. Voges, D., P. Zwickel, and W. Baumeister, *The 26S proteasome: a molecular machine designed for controlled proteolysis*. Annu. Rev. Biochem., 2000. **68**: p. 1015-1068.
14. Tian, L., et al., *MDM2 interacts with and downregulates a sarcomeric protein, TCAP*. Biochem Biophys Res Commun, 2006. **345**: p. 355-61.
15. Toth, A., et al., *Differential regulation of cardiomyocyte survival and hypertrophy by MDM2, an E3 ubiquitin ligase*. J Biol Chem, 2006. **281**: p. 3679-89.
16. Meacham, G., C. Patterson, and W. Zhang, *The Hsc 70 co-chaperone CHIP targets immature CFTR for proteasomal degradation*. Nature Cell. Biol., 2001. **3**: p. 100-105.
17. Murata, S., Y. Minami, and M. Minami, *CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded proteins*. EMBO Rep., 2001. **2**: p. 1133-1138.
18. Sandri, M., et al., *PGC-1-alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription*. PNAS, 2006. **103**: p. 16260-16265.
19. Lecker, S., et al., *Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression*. The FASEB Journal, 2004. **18**: p. 39-51.
20. Hartmann-Petersen, R. and C. Gordon, *Proteins interacting with the 26S proteasome*. Cell. Mol. Life Sci., 2004. **61**: p. 1589-95.

21. Ciechanover, A., H. Heller, and S. Elias, *ATP-dependent conjugation of reticulocyte proteins with the polypeptide required for protein degradation*. Proc. Natl. Acad. Sci. USA, 1980. **77**: p. 1365-68.
22. Waxman, L., J. Fagan, and A. Goldberg, *Demonstration of two distinct high molecular weight proteases in rabbit reticulocytes, one of which degrades ubiquitin conjugates*. J. Biol. Chem., 1987. **262**: p. 2451-57.
23. Arnason, T. and M. Ellison, *Stress resistance in Saccharomyces cerevisiae is strongly correlated with assembly of a novel type of multiubiquitin chain*. Mol. Cell. Biol., 1994. **14**: p. 7876-7883.
24. Peng, J., D. Schwartz, and J. Elias, *A proteomics approach to understanding protein ubiquitination*. Nat. Biotechnol., 2003. **21**: p. 921-926.
25. Johnson, E., P. Ma, and I. Ota, *A proteolytic pathway that recognizes ubiquitin as a degradation signal*. J. Biol. Chem., 1995. **270**: p. 17442-17456.
26. Liu, Z., A. Haas, and L. Diaz, *Characterization of a novel keratinocyte ubiquitin carrier protein*. J. Biol. Chem., 1996. **271**: p. 2817-2822.
27. Schnell, J. and L. Hicke, *Non-traditional functions of ubiquitin and ubiquitin-binding proteins*. J. Biol. Chem., 2003. **278**: p. 35857-35860.
28. Kloetzel, P., *Antigen processing by the proteasome*. Nat. Rev. Mol. Cell Biol., 2001. **2**: p. 179-188.
29. Jesenberger, V. and S. Jentsch, *Deadly encounter: ubiquitin meets apoptosis*. Nat. Rev. Mol. Cell Biol., 2002. **3**: p. 112-121.
30. Hicke, L. and R. Dunn, *Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins*. Annu. Rev. Cell Dev. Biol., 2003. **19**(141-172).
31. Muratani, M. and W. Tansey, *How the ubiquitin-proteasome system controls transcription*. Nat. Rev. Mol. Cell Biol., 2003. **4**: p. 192-201.
32. Reed, S., *Ratchets and clocks: The cell cycle, ubiquitylation and protein turnover*. Nat. Rev. Mol. Cell Biol., 2003. **4**: p. 855-864.
33. Passmore, L. and D. Barford, *Getting into position: the catalytic mechanisms of protein ubiquitylation*. Biochem. J., 2004. **379**: p. 513-525.
34. Goff, S., R. Voellmy, and A. Goldberg, *Chapter 8*, in *Ubiquitin*, M. Reichsteiner, Editor. 1988, Plenum: New York.
35. Ananathan, J., A. Goldberg, and R. Voellmy, *Abnormal proteins serve as eucaryotic stress signals and trigger the activation of heat-shock genes*. Science, 1986. **232**: p. 522-24.
36. Arrigo, A., K. Tanaka, and A. Goldberg, *Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome)*. Nature, 1988. **14**(331): p. 192-4.
37. O'Connor, O., *The Emerging Role of Bortezomib in the Treatment of Indolent Non-Hodgkin's and Mantle Cell Lymphomas*. Curr. Treat. Opt. Oncol., 2005. **5**(269-281).
38. Zwickl, P., A. Goldberg, and W. Baumeister, *The World of Regulatory Proteolysis*. Proteasomes, ed. D. Wolf and W. Hilt. 2000, Georgetown, Texas: Landes Bioscience.
39. Mykles, D. and M. Haire, *Sodium dodecyl sulfate and heat induce two distinct forms of lobster muscle catalytic proteinase: the heat-activated form degrades myofibrillar proteins*. Arch. Biochem. Biophys., 1991. **288**(2): p. 543-51.
40. Groll, M., *A gated channel into the proteasome core particle*. Nature Struct. Biol., 2000. **7**: p. 1062-1067.

41. Benaroudj, N., P. Zwickl, and E. Seemueller, *ATP hydrolysis by the proteasome regulatory complex PAN serves multiple functions in protein degradation*. *Mol. Cell*, 2003. **11**: p. 69-78.
42. Schubert, U., *Rapid degradation of a large fraction of newly synthesized proteins by proteasomes*. *Nature*, 2000. **44**: p. 770-774.
43. Ritossa, F., *A new puffing pattern induced by temperature shock and DNP in Drosophila*. *Experientia*, 1962. **18**: p. 571-573.
44. Hightower, L. and L. Hendershot, *Molecular chaperones and the heat shock response at Cold Spring Harbor*. *Cell-Stress-Chaperones*, 1997. **2**(1): p. 1-11.
45. Snoeckx, L., R. Cornelussen, and F. Van-Nieuwenhoven, *Heat shock proteins and cardiovascular pathology*. *Physiol. Rev.*, 2001. **81**(4): p. 1461-97.
46. Koyasu, S., E. Nishida, and T. Kadowaki, *TWO mammalian heat shock proteins, HSP90 and HSP100, are actin-binding proteins*. *Proc. Natl. Acad. Sci. USA*, 1986. **83**(21): p. 8054-8.
47. Czar, M., M. Welsh, and W. Pratt, *Immunofluorescence localization of the 90-kDa heat-shock protein to cytoskeleton*. *Eur. J. Cell. Biol.*, 1996. **70**(4): p. 322-30.
48. Pratt, W., M. Czar, and L. Stancato, *The hsp56 immunophilin component of steroid receptor heterocomplexes: could this be the elusive nuclear localization signal-binding protein?* *J. Steroid Biochem. Mol. Biol.*, 1993. **46**(3): p. 269-79.
49. Minami, Y., J. Hohfeld, and K. Ohtsuka, *Regulation of the heat-shock protein 70 reaction cycle by the mammalian DnaJ homolog HSP 40*. *J. Biol. Chem.*, 1996. **271**: p. 19617-24.
50. Gunther, E. and L. Walter, *Genetic aspects of the hsp70 multigene family in vertebrates*. *Experientia*, 1994. **50**: p. 987-1001.
51. Feige, U. and B. Polla, *Hsp70--a multi-gene, multi-structure, multi-function family with potential clinical applications*. *Experientia*, 1994. **50**: p. 979-986.
52. Bennardini, F., A. Wrzosek, and M. Chiesi, *Alpha B-crystallin in cardiac tissue. Association with actin and desmin filaments*. *Circ. Res.*, 1992. **71**(2): p. 288-94.
53. Benjamin, I. and D. McMillan, *Stress (heat shock) proteins: molecular chaperones in cardiovascular biology and disease*. *Circ. Res.*, 1998. **83**(2): p. 117-32.
54. Nakai, A., M. Tanabe, and Y. Kawazoe, *HSF4, a new member of the human heat shock factor family which lacks properties of a transcriptional activator*. *Mol. Cell. Biol.*, 1997. **17**(1): p. 469-81.
55. Sistonen, L., K. Sarge, and R. Morimoto, *Human heat shock factors 1 and 2 are differentially activated and can synergistically induce hsp 70 gene transcription*. *Mol. Cell. Biol.*, 1994. **14**(3): p. 2087-99.
56. Wu, C., *Heat shock transcription factors: structure and regulation*. *Annu. Rev. Cell. Dev. Biol.*, 1995. **11**: p. 441-69.
57. Goodson, M., O. Park-Sage, and K. Sarge, *Tissue-dependent expression of heat shock factor 2 isoforms with distinct transcriptional activities*. *Mol. Cell. Biol.*, 1995. **15**(10): p. 5288-93.
58. Hatayama, T., Y. Asai, and T. Wakatsuki, *Regulation of hsp70 induction in thermotolerant HeLa cells*. *Biochem. Biophys. Acta*, 1993. **1179**(2): p. 109-16.
59. Lin, H., L. Han, and M. Blank, *Magnetic field activation of protein-DNA binding*. *J. Cell. Biochem*, 1998. **70**(3): p. 297-303.
60. Shi, Y., D. Mosser, and R. Morimoto, *Molecular chaperones as HSF1-specific transcriptional repressors*. *Genes & Development*, 1998. **12**: p. 654-666.

61. Morimoto, R., *Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators*. *Genes & Development*, 1998. **12**: p. 3788-3796.
62. Powell, S., P. Wang, and H. Schwalb, *Oxidized and ubiquitinated proteins may predict recovery of postischemic cardiac function: essential role of the proteasome*. *Antioxidants and Redox Signaling*, 2005. **7**: p. 538-546.
63. Kisselev, A.F. and A.L. Goldberg, *Proteasome inhibitors: from research tools to drug candidates*. *Chem. Biol.*, 2001. **8**(8): p. 739-58.
64. Chen, P. and M. Hochstrasser, *Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly*. *Cell*, 1996. **86**: p. 961-972.
65. Kessler, B., et al., *Extended-peptide based inhibitors efficiently target the proteasome and reveal overlapping specificities of catalytic subunits*. *Chem. Biol.*, 2001. **8**.
66. Koepp, D., J. Harper, and S. Elledge, *How the cyclin became a cyclin: regulated proteolysis in the cell cycle*. *Cell*, 1999. **14**: p. 431-4.
67. Hershko, A. and A. Ciechanover, *The ubiquitin system*. *Annu Rev Biochem*, 1998. **67**: p. 425-79.
68. Harris, K., I. Shoji, and P. Howley, *Ubiquitin-mediated degradation of active Src tyrosine kinase*. *Proc. Natl. Acad. Sci. USA*, 1999. **23**: p. 13738-43.
69. Lu, Z., D. Liu, and D. Foster, *Activation of protein kinase C triggers its ubiquitination and degradation*. *Mol. Cell. Biol.*, 1998. **18**(2): p. 839-45.
70. Pagano, M., S. Tam, and M. Rolfe, *Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27*. *Science*, 1995. **269**: p. 631-2.
71. Chauhan, D., T. Hideshima, and K. Anderson, *Proteasome inhibition in multiple myeloma: therapeutic implication*. *Annu Rev Pharmacol Toxicol*, 2005. **45**: p. 465-76.
72. Meiners, S., et al., *Ubiquitin-proteasome pathway as a new target for the prevention of restenosis*. *Circulation*, 2002. **105**(4)(Jan 29): p. 408-10.
73. Meiners, S., et al., *Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome*. *Hypertension*, 2004. **44**(4)(Oct.): p. 471-7.
74. Rajkumar, S., P. Richardson, and K. Anderson, *Proteasome inhibition as a novel therapeutic target in human cancer*. *J. Clin. Oncol.*, 2005. **20**: p. 630-9.
75. Park, D. and H. Lenz, *The role of proteasome inhibitors in solid tumors*. *Ann. Med.*, 2004. **36**: p. 296-303.
76. Palombella, V., et al., *Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis*. *Proc Natl Acad Sci USA*, 1998. **95**: p. 15671-15676.
77. Meng, L., R. Mohan, and C. Crews, *Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity*. *Proc. Natl. Acad. Sci. USA*, 1999. **96**(18): p. 10403-8.
78. McRea, B., et al., *Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis*. *J Exp Med*, 1995. **182**: p. 75-85.
79. Elliott, P.J., T. Zollner, and W. Boehncke, *Proteasome inhibition: a new anti-inflammatory strategy*. *J Mol Med*, 2003. **81**: p. 235-245.
80. Mitch, W. and A. Goldberg, *Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway*. *N. Engl. J. Med.*, 1996. **335**(25): p. 1897-905.

81. Filippatos, G., S. Anker, and D. Kremastinos, *Pathophysiology of peripheral muscle wasting in cardiac cachexia*. *Curr. Opin. Clin. Nutr. Metab. Care*, 2005. **8**: p. 249-254.
82. Campbell, B., et al., *Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart*. *J Mol Cell Cardiol*, 1999. **31**: p. 467-476.
83. Pye, J., et al., *Proteasome inhibition ablates activation of NF-kappaB induced during myocardial reperfusion and reduces reperfusion injury*. *Am J Physiol Heart Circ Physiol*, 2003.
84. Kawazoe, Y., A. Nakai, and K. Nagata, *Proteasome inhibition leads to the activation of all members of the heat-shock-factor family*. *Eur. J. Biochem.*, 1998. **255**(2): p. 356-62.
85. Bush, K., A.L. Goldberg, and S.K. Nigam, *Proteasome inhibition leads to a heat-shock response, induction of endoplasmic reticulum chaperones, and thermotolerance*. *J. Biol. Chem.*, 1997. **272**(14): p. 9086-92.
86. Kuznetsov, G., et al., *Perturbations in maturation of secretory proteins and their association with endoplasmic reticulum chaperones in a cell culture model for epithelial ischemia*. *Proc Natl Acad Sci USA*, 1996. **93**: p. 8584-8589.
87. Meiners, S., et al., *Inhibition of Proteasome Activity Induces Concerted Expression of Proteasome Genes and de Novo Formation of Mammalian Proteasomes*. *J Biol Chem*, 2003. **278**: p. 21517-21525.
88. Meriin, A.B., V.L. Gabai, and M.Y. Sherman, *Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis*. *J. Biol. Chem.*, 1998. **13**(273): p. 6373-9.
89. Hightower, L., *Heat shock, stress proteins, chaperones, and proteotoxicity*. *Cell*, 1991(66): p. 191-197.
90. Ciechanover, A. and A.L. Schwartz, *The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death*. *Proc. Natl. Acad. Sci. USA*, 1998. **95**(6): p. 2727-30.
91. Goldberg, A.L., et al., *New insights into the mechanisms and importance of the proteasome in intracellular protein degradation*. *Biol. Chem.*, 1997. **378**(3-4).
92. Volloch, V., et al., *Reduced thermotolerance in aged cells results from a loss of an hsp72-mediated control of JNK signaling pathway*. *Cell-Stress-Chaperones*, 1998. **3**(4): p. 265-71.
93. Zhou, M., X. Wu, and H.N. Ginsberg, *Evidence that a rapidly turning over protein, normally degraded by proteasomes, regulates hsp72 gene transcription in HepG2 cells*. *J. Biol. Chem.*, 1996. **271**(40): p. 24769-75.
94. Kim, D. and G.C. Li, *Proteasome inhibitors lactacystin and MG132 inhibit the dephosphorylation of HSF1 after heat shock and suppress thermal induction of heat shock gene expression*. *Biochem. Biophys. Res. Commun.*, 1999. **264**(2): p. 352-8.
95. Lee, D.H. and A.L. Goldberg, *Proteasome inhibitors cause induction of heat shock proteins and trehalose, which together confer thermotolerance in *Saccharomyces cerevisiae**. *Mol. Cell. Biol.*, 1998. **18**(1): p. 30-8.
96. Manzerra, P., S. Rush, and I. Brown, *Tissue-specific differences in heat shock protein hsc70 and hsp70 in the control and hyperthermic rabbit*. *J. Cell. Physiol.*, 1997. **170**: p. 130-137.
97. Tanguy, R. and E. Kandjlan, *Tissue-specific expression of heat shock proteins of the mouse in the absence of stress*. *Dev. Genet.*, 1993. **14**: p. 112-118.

98. Gray, C., M. Amrani, and M. Yacoub, *Heat stress proteins and myocardial protection: experimental model or potential clinical tool?* Int. J. Biochem. Cell. Biol., 1999. **31**: p. 559-573.
99. Kawazoe, Y., et al., *Proteasome inhibition leads to the activation of all members of the heat-shock-factor family.* Eur. J. Biochem., 1998. **255**(2): p. 356-62.
100. Tanikawa, J., et al., *p53 suppresses the c-Myb-induced activation of heat shock transcription factor 3.* J. Biol. Chem., 2000. **275**(20): p. 15578-85.
101. Awasthi, N. and B. Wagner, *Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens.* Invest Ophthalmol Vis Sci, 2005. **46**(6): p. 2082-91.
102. Lüss, H., W. Schmitz, and J. Neumann, *A proteasome inhibitor confers cardioprotection.* Cardiovascular Research, 2002. **54**: p. 140–151.
103. Dorion, S., et al., *A short lived protein involved in the heat shock sensing mechanism responsible for stress-activated protein kinase 2 (SAPK2/p38) activation.* J Biol Chem, 1999(274): p. 37591-37597.
104. Sheikh-Hamad, D., J. Di Mari, and W. Suki, *p38 kinase activity is essential for osmotic induction of mRNAs for HSP70 and transporter for organic solute betaine in Madin-Darby canine kidney cells.* J Biol Chem, 1998(273): p. 1832-1837.
105. Uehara, T., et al., *Possible involvement of p38 MAP kinase in HSP70 expression induced by hypoxia in rat primary astrocytes.* Brain Res, 1999(823): p. 226-230.
106. Elbirt, K. and H. Bonkovsky, *Heme oxygenase: recent advances in understanding its regulation and role.* Proc Assoc Am Physicians, 1999(111): p. 438-447.
107. Mosser, D.D., J. Duchaine, and B. Massie, *The DNA-binding activity of the human heat shock transcription factor is regulated in vivo by hsp70.* Mol. Cell. Biol., 1993. **13**(9): p. 5427-38.
108. Chu, B., et al., *Sequential phosphorylation by mitogen-activated protein kinase and glycogen synthase kinase 3 re-presses transcriptional activation by heat shock factor-1.* J. Biol. Chem., 1996. **271**(48): p. 30847-57.
109. Knauf, U., E. Newton, and J. Kyriakis, *Repression of human heat shock factor 1 activity at control temperature by phosphorylation.* Genes & Development, 1996. **10**(21): p. 2782-93.
110. Satyal, S., D. Chen, and S. Fox, *Negative regulation of the heat shock transcriptional response by HSBP1.* Genes & Development, 1998. **12**: p. 1962-1974.
111. Koishi, M., N. Hosokawa, and M. Sato, *Quercetin, an inhibitor of heat shock protein synthesis, inhibits the acquisition of thermotolerance in a human colon carcinoma cell line.* Jpn J Cancer Res, 1992. **82**: p. 1216–1222.
112. Hansen, R., et al., *Quercetin inhibits heat shock protein induction but not heat shock factor DNA-binding in human breast carcinoma cells.* Biochem Biophys Res Commun, 1997. **239**: p. 851-856.
113. Wu, B. and A. Yu, *Quercetin inhibits c-fos, heat shock protein, and glial fibrillary acidic protein expression in injured astrocytes.* J Neurosci Res, 2000. **62**: p. 730-736.
114. Yoshida, H., T. Murachi, and I. Tsukahara, *Limited proteolysis of bovine lens alpha-crystallin by calpain, a Ca<sup>2+</sup>-dependent cysteine proteinase, isolated from the same tissue.* Biochim Biophys Acta, 1984(798): p. 252-259.

115. Yoshida , H., et al., *Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction*. Cardiovasc Res., 2003. **59**: p. 419-27.
116. Carper, D., M. John, and Z. Chen, *Gene expression analysis of an H(2)O(2)-resistant lens epithelial cell line*. Free Radic Biol Med, 2001(31): p. 90-97.
117. Andley, U., H. Patel, and J. Xi, *The R116C mutation in alpha A-crystallin diminishes its protective ability against stress-induced lens epithelial cell apoptosis*. J Biol Chem, 2002(277): p. 10178-10186.
118. Mehlen, P., K. Schulze-Osthoff, and A. Arrigo, *Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/ APO-1- and staurosporine-induced cell death*. J Biol Chem, 1996.
119. Cumming, -.D.-V.H., -R-J; Coffin,-R-S; Yellon,-D-M; Latchman,-D-S: . *Basic-Res-Cardiol*. 1996 Sep-Oct; 91(5): 367-73, *Pharmacological preconditioning of primary rat cardiac myocytes by FK506*. Basic Res. Cardiol., 1996. **91**(5): p. 367-73.
120. Heads, R.J., D.M. Yellon, and D.S. Latchman, *Differential cytoprotection against heat stress or hypoxia following expression of specific stress protein genes in myogenic cells*. J. Mol. Cell. Cardiol., 1995. **27**(8): p. 1669-78.
121. Latchman, D.S., *Heat shock proteins and cardiac protection*. Cardiovascular Research, 2001. **51**(4): p. 637-46.
122. Maulik, N., et al., *Oxidative stress adaptation improves postischemic ventricular recovery*. Mol. Cell. Biochem., 1995. **144**(1): p. 67-74.
123. Nishizawa, J., et al., *Reperfusion causes significant activation of heat shock transcription factor 1 in ischemic rat heart*. Circulation, 1996. **94**(9): p. 2185-92.
124. Samali, A., et al., *Thermotolerance and cell death are distinct cellular responses to stress: dependence on heat shock proteins*. FEBS Lett, 1999. **461**: p. 306-310.
125. Laing, J., et al., *Proteolysis of connexin43-containing gap junctions in normal and heat-stressed cardiac myocytes*. Cardiovasc Res., 1998. **38**: p. 711-718.
126. Martin, J.L., et al., *Small heat shock proteins and protection against ischemic injury in cardiac myocytes*. Circulation, 1997. **96**(12): p. 4343-8.
127. Lavoie, J.N., et al., *Induction of Chinese hamster HSP27 gene expression in mouse cells confers resistance to heat shock. HSP27 stabilization of the microfilament organization*. J. Biol. Chem., 1993. **268**(5): p. 3420-9.
128. Mehlen, P., K. Schulze-Osthoff, and A.P. Arrigo, *Small stress proteins as novel regulators of apoptosis. Heat shock protein 27 blocks Fas/APO-1- and staurosporine-induced cell death*. J. Biol. Chem., 1996. **271**(28): p. 16510-4.
129. Jäättelä, M., et al., *Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases*. EMBO, 1998. **17**(21): p. 6124-34.
130. Nicholson, D., *Caspase structure, proteolytic substrates, and function during apoptotic cell death*. Cell Death Differ., 1999(6): p. 1028–1042.
131. Thornberry, N. and Y. Lazebnik, *Caspases: enemies within*. Science, 1998(281): p. 1312-1316.
132. Awasthi, N. and B. Wagner, *Interferon-gamma induces apoptosis of lens alpha-TN4–1 cells and proteasome inhibition has an antiapoptotic effect*. Invest Ophthalmol Vis Sci, 2004(45): p. 222–229.
133. Kim, E., et al., *Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells*. J Cell Biochem, 2002(85).
134. Boudreau, N., et al., *Suppression of ICE and apoptosis in mammary epithelial cells by extracellular matrix*. Science, 1995(267): p. 891-893.

135. Gabai, V.L., et al., *Hsp72-mediated suppression of c-Jun N-terminal kinase is implicated in development of tolerance to caspase-independent cell death*. Mol. Cell. Biol., 2000. **20**(18): p. 6826-36.
136. Bellmann, K., et al., *p38-dependent enhancement of cytokine-induced nitric-oxide synthase gene expression by heat shock protein 70*. J. Biol. Chem., 2000. **275**(24): p. 18172-9.
137. Buzzard, K.A., et al., *Heat shock protein 72 modulates pathways of stress-induced apoptosis*. J. Biol. Chem., 1998. **273**(27).
138. Kato, K., et al., *Immunoreactive alpha A crystallin in rat non-lenticular tissues detected with a sensitive immunoassay method*. Biochim. Biophys. Acta, 1991(1080): p. 173-180.
139. Srinivasan, A., C. Nagineni, and S. Bhat, *aA-crystallin is expressed in non-ocular tissues*. J. Biol. Chem., 1992. **267**: p. 23337–23341.
140. Klemenz, R., et al., *Alpha B-crystallin is a small heat shock protein*. Proc. Natl. Acad. Sci. USA, 1991. **88**: p. 3652–3656.
141. Dasgupta, S., T. Hohman, and D. Carper, *Hypertonic stress induces aB-crystallin expression*. Exp. Eye Res., 1992(54): p. 461-470.
142. Head, M., E. Corbin, and J. Goldman, *Coordinate and independent regulation of aB-crystallin and HSP27 expression in response to physiological stress*. J. Cell Physiol., 1994. **159**: p. 41-50.
143. Lin, K., J. Baraban, and R. Ratan, *Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration*. Cell Death Differ, 1998(5): p. 577-583.
144. Maki, C.G., J.M. Huibregtse, and P.M. Howley, *In vivo ubiquitination and proteasome-mediated degradation of p53(1)*. Cancer Res, 1996. **56**(11): p. 2649-54.
145. Salghetti, S.E., S.Y. Kim, and W.P. Tansey, *Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc*. Embo J, 1999. **18**(3): p. 717-26.
146. Wojcik, C., *Regulation of apoptosis by the ubiquitin and proteasome pathway*. J. Cell. Mol. Med., 2002. **6**(1): p. 25-48.
147. Nakano, A., et al., *SB 203580, an inhibitor of p38 MAPK, abolishes infarct-limiting effect of ischemic preconditioning in isolated rabbit hearts*. Basic Res Cardiol, 2000. **95**(6): p. 466-71.
148. Wu, W.T., et al., *Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition*. Biochem J, 2004. **379**: p. 587-93.
149. Geng, Y.L., et al., *Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon- $\gamma$ , tumor necrosis factor- $\alpha$ , and interleukin-1 $\beta$* . Arterioscler. Thromb. Vasc. Biol., 1996. **16**: p. 19-27.
150. Petrache, I., et al., *Heme oxygenase-1 inhibits TNF- $\alpha$ -induced apoptosis in cultured fibroblasts*. Am. J. Physiol., 2000. **278**: p. 312-319.
151. Shiraishi, F., et al., *Heme oxygenase-1 gene ablation or expression modulates cisplatin-induced renal tubular apoptosis*. Am. J. Physiol., 2000. **278**: p. 726-736.
152. Otterbein, L.E., et al., *Exogenous administration of heme oxygenase-1 by gene transfer provides protection against hyperoxia-induced lung injury*. J. Clin. Invest., 1999. **103**: p. 1047-1054.



153. Araujo, J.A., et al., *Systemic rather than local heme oxygenase-1 overexpression improves cardiac allograft outcomes in a new transgenic mouse*. J. Immunol., 2003. **171**: p. 1572-1580.
154. Meiners, S., et al., *Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells*. Free Radic Biol Med, 2006. **40**: p. 2232-2241.
155. Ardehali, H., B. O'Rourke, and E. Marban, *Cardioprotective Role of the Mitochondrial ATP-Binding Cassette Protein 1*. Circ. Res., 2005. **97**: p. 740-742.
156. Adams, J., V. Palombella, and E. Sausville, *Proteasome inhibitors: a novel class of potent and effective antitumor agents*. Cancer Res, 1999. **59**: p. 2615-2622.
157. Ling, Y., L. Liebes, and B. Ng, *PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis*. Mol Cancer Ther, 2002. **1**: p. 841-849.
158. Ling, Y., L. Liebes, and J. Jiang, *Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines*. Clin Cancer Res, 2003. **9**: p. 1145-1154.
159. Ma, M., H. Yang, and K. Parker, *the proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents*. Clin Cancer Res, 2003. **9**: p. 1136-1144.
160. Russo, S., J. Tepper, and A.J. Baldwin, *Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB*. Int J Radiat Oncol Biol Phys, 2001. **50**: p. 183-193.
161. Adams, J., *Development of the proteasome inhibitor PS-341*. Oncologist, 2002. **7**(1): p. 9-16.
162. Richardson, P., B. Barlogie, and J. Berenson, *A Phase 2 study of bortezomib in relapsed, refractory myeloma*. N Engl J Med, 2003. **348**: p. 2609-2617.
163. Jagannath, S., B. Barlogie, and J. Berenson, *A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma*. Br J Haematol, 2004. **127**: p. 165-172.
164. Richardson, P., P. Sonneveld, and M. Schuster, *Bortezomib or high-dose dexamethasone for relapsed multiple myeloma*. N Engl J Med, 2005. **353**(2487-2498).
165. Adams, J. and M. Kauffman, *Development of the proteasome inhibitor Velcade (Bortezomib)*. Cancer Invest, 2004. **22**(2): p. 304-11.
166. Adams, J., *The proteasome: a suitable antineoplastic target*. Nat Rev Cancer, 2004. **4**(5): p. 349-60.
167. Orlowski, R., P. Voorhees, and R. Garcia, *Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies*. Blood, 2005. **15**: p. 3058-3065.
168. Zangari, M., B. Barlogie, and H. K, *Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM)*. Blood, 2004. **104**: p. 413a-414a.
169. Jagannath, S., P. Richardson, and B. Barlogie, *Phase II trials of bortezomib in combination with dexamethasone in multiple myeloma (MM): assessment of additional benefits to combination in patients with sub-optimal responses to bortezomib alone*. Proc Am Soc Clin Oncol, 2003. **22**: p. 582.
170. Tan, C. and T. Waldmann, *Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia*. Cancer Res, 2002. **62**: p. 1083-1086.

171. Goy, A., et al., *Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma*. J Clin Oncol, 2005. **23**: p. 667-675.
172. Williams, S., et al., *Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts*. Mol Cancer Ther, 2003. **2**: p. 835-843.
173. Ludwig, H., et al., *Proteasome Inhibition and Its Clinical Prospects in the Treatment of Hematologic and Solid Malignancies*. Cancer, 2005. **104**: p. 1794-1807.
174. Elliott, P.J., et al., *Proteasome inhibition: A novel mechanism to combat asthma*. J. Allergy Clin. Immunol., 1999. **104**(2): p. 294-300.
175. Vogt, V.M., *Ubiquitin in retrovirus assembly: actor or bystander?* Proc. Natl. Acad. Sci. USA, 2000. **97**(24): p. 12945-7.
176. Zollner, T., et al., *Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model*. J Clin Invest, 2002. **109**: p. 671-679.
177. Phillips, J., et al., *Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia*. Stroke, 2000. **31**: p. 1686-1693.
178. Zhang, L., Z. Zhang, and R. Zhang, *Postischemic (6-Hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia*. Stroke, 2001. **32**: p. 2926-2931.
179. Stangl V, et al., *Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin–proteasome pathway*. FASEB, 2004. **18**: p. 272-279.